Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Apr 21, 2017

Keywords

ClinConnect Summary

The GUIDE-CRT II clinical trial is studying a new approach to help patients with chronic heart failure respond better to a treatment called Cardiac Resynchronization Therapy (CRT). The researchers believe that using advanced imaging techniques—specifically, combining SPECT imaging (which looks at blood flow in the heart) with fluoroscopy (a type of X-ray)—to place the lead in the heart more accurately can improve the effectiveness of CRT compared to the usual method. This trial is currently looking for participants aged 65 to 74 who have moderate to severe heart failure and meet certain health criteria, such as having a weakened heart function (LVEF of 35% or less) and a specific heart rhythm.

Eligible participants can expect to undergo the new imaging techniques to help guide the placement of the CRT device. It’s important to note that some individuals may not qualify, such as those with certain heart conditions, recent heart surgeries, or those who are pregnant. If you or a loved one are interested, this trial offers a chance to explore a potentially beneficial treatment option for heart failure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient has signed informed consent
• • moderate to severe HF (NYHA Class II, III or IV)
• • LVEF ≤35%
• • QRS duration ≥130 ms
• • sinus rhythm
• Exclusion Criteria:
• • Patient is under a minimum age requirement (\<18 years old)
• • Patient has mechanical right heart valve
• • Patient has experienced unstable angina, acute MI, CABG or PCI within the past 3 months
• • Patient is on continuous or intermittent (i.e., more than two infusions per week) intravenous inotropic drug therapy
• • Patient known to have chronic permanent atrial arrhythmias (i.e., cases of long-standing atrial fibrillation of greater than 1 year, including those in which cardioversion has not been indicated or attempted).
• • Patient is enrolled in any other study
• • Patient has a life expectancy of less than 12 months
• • Women who are pregnant, or with child-bearing potential and who are not on a form of birth control
• • Patient with CRT device implanted previously
• • Patient has had a heart transplant
• • Patient has third degree AVB with normal cardiac function